(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/123272 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/5025* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/GB2021/053252

(22) International Filing Date:
10 December 2021 (10.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2019622.6 11 December 2020 (11.12.2020) GB

(71) Applicant: **ADORX THERAPEUTICS LIMITED** [GB/GB]; 137a George Street, Edinburgh EH2 4JY (GB).

(72) Inventors: **MCCARTHY, Clive**; c/o AdoRx Therapeutics Limited, 137a George Street, Edinburgh EH2 4JY (GB). **MOULTON, Benjamin**; c/o Apex Molecular Limited, Block 19 Alderley Park, Mereside, Alderley Edge Cheshire SK10 4TG (GB).

(74) Agent: **HGF LIMITED**; Document Handling - HGF (Manchester), 1 City Walk, Leeds West Yorkshire LS11 9DX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/123272 A1

(54) Title: ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR



(57) Abstract: The present invention relates to compounds of formula I shown below: wherein R_0, R_1, R_2, R_3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.